中国药科大学学报2024，Vol.55Issue(1)：36-44,9.DOI:10.11665/j.issn.1000-5048.2023112904
基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展
Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis
摘要
Abstract
C-C motif chemokine ligand 2(CCL2)and its receptor CCR2 are closely related to tumorigenesis and tumor progression.The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms:CCL2 binds to CCR2 on the surface of tumor cells,and thus promotes tumor growth/survival and metastasis;more importantly,CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment,and inhibits the function and activity of immune cells,promoting tumor progression.The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment,with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis,in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.关键词
CCL2/CCR2/肿瘤免疫治疗/肿瘤微环境/免疫抑制细胞Key words
CCL2/CCR2/cancer immunotherapy/tumor microenvironment/immunosuppressive cells分类
医药卫生引用本文复制引用
崔珍珍,赵一凡,孙玉,孟佳怡,康迪,胡立宏..基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展[J].中国药科大学学报,2024,55(1):36-44,9.基金项目
This work was supported by the National Natural Science Foundation of China(No.82104270)and the Graduate Research and Innovation Projects of Jiangsu Province(KYCX22_2035)国家自然科学基金项目(No.82104270) （No.82104270）
江苏省研究生实践创新计划项目(KYCX22_2035) （KYCX22_2035）
